Please login to the form below

Not currently logged in
Email:
Password:

Amylin

This page shows the latest Amylin news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca and its diabetes plans

AstraZeneca and its diabetes plans

This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the long-acting exenatide franchise (Byetta and

Latest news

More from news
Approximately 2 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Adocia names senior members of new US subsidiary Adocia names senior members of new US subsidiary

    Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon's phase III studies and safety analysis, a once weekly GLP-1 injectable formulation. ... Daly's experience in the diabetes field also includes several years at

  • Profil Institute appoints former Amylin CEO Profil Institute appoints former Amylin CEO

    Profil Institute appoints former Amylin CEO. Dan Bradbury joins board of diabetes company. ... Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics